Tirzepatide represents a new class of peptide therapeutics—a dual GLP-1/GIP receptor agonist that provides superior efficacy compared to selective GLP-1 agonists. Eli Lilly's tirzepatide is projected to be the top-selling drug in 2026, generating more than $45 billion in global sales[reference:112].
Tirzepatide is a 39-amino acid peptide that activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual agonism provides complementary effects: GLP-1 agonism promotes insulin secretion and satiety, while GIP agonism enhances insulin secretion and may have additional metabolic benefits. The combination results in superior glycemic control and weight loss compared to selective GLP-1 agonists.
The structure of tirzepatide incorporates several modifications that enhance its properties. The peptide includes a fatty acid moiety that promotes albumin binding and extends half-life, enabling once-weekly dosing. The sequence is optimized for balanced activity at both receptors, with modifications that resist proteolytic degradation.
Clinical trials have demonstrated the remarkable efficacy of tirzepatide. In the SURPASS and SURMOUNT trials, tirzepatide showed superior reductions in HbA1c and greater weight loss compared to selective GLP-1 agonists. The drug has been approved for type 2 diabetes (Mounjaro) and obesity (Zepbound), with additional indications under investigation.
For researchers, tirzepatide and its analogs are valuable tools for studying incretin biology, investigating multi-target approaches, and developing next-generation metabolic therapeutics. At PeptideHub, we offer custom synthesis of tirzepatide and related peptides for research applications, with high purity and full analytical documentation.